Connect
MJA
MJA

Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010

Stephen P Fitzgerald
Med J Aust 2012; 197 (6): . || doi: 10.5694/mja12.11014
Published online: 17 September 2012

To the Editor: Could Handelsman comment on whether he considered opioid-associated hypoandrogenism when describing the increasing prescribing of testosterone?1 Opioid-induced androgen deficiency has become more recognised, and is one of the most common causes of testosterone deficiency among men in many communities.2,3 It may be that the increase in opioid prescribing4 has complemented the promotion of testosterone therapy.


  • Royal Adelaide Hospital, Adelaide, SA.



Competing interests:

No relevant disclosures.

  • 1. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010. Med J Aust 2012; 196: 642-645.
  • 2. Daniell H. Opioid-induced androgen deficiency. Curr Opin Endocrinol Diabetes 2006; 13: 262-266.
  • 3. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
  • 4. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesia and related harms in Australia. Med J Aust 2011; 195: 280-284.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.